Chimerix

  • Home
  • Scientific Foundation

Lipid Antiviral Conjugate Technology

Chimerix is applying its powerful Lipid-Antiviral-Conjugate Technology to existing antiviral compounds with the goal of increasing their bioavailability, tolerability and activity.  By improving the pharmaceutical attributes of drugs with known mechanisms of action to create new chemical entities, we believe we can dramatically change the way certain deadly viral diseases are treated.

Chimerix’s proprietary technology is used to covalently modify a drug molecule so that it mimics a naturally occurring phospholipid metabolite. The lipid mimic can then utilize natural uptake pathways to achieve oral availability.

We believe Lipid-Antiviral-Conjugate Technology-based drugs may be developed with reduced risks since they have a known mechanism of action. Preclinical studies and in vitro experiments on a number of drugs have shown specific improvements in biological activity compared with the parent drug.  CMX001 has demonstrated higher bioavailability than the parent drug cidofovir in initial human studies, and may offer a more convenient oral treatment option when compared to cidofovir, which must be delivered intravenously. Like CMX001, new drugs that utilize Chimerix’s Lipid-Antiviral-Conjugate Technology are protected as new chemical entities with strong composition of matter patents.

Clinical Trials

himerix has completed a Phase 1 clinical study of orally-administered CMX001 in 84 healthy volunteers. The blinded, randomized, parallel-group, placebo-controlled study evaluated the safety and pharmacokinetics of single and multiple doses of CMX001. CMX001 was well tolerated at all doses. In addition, CMX001 was well absorbed after oral dosing, with dose-dependent pharmacokinetics. Read More


Licensing Opportunities

Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology and the Townsend Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines. Read More